<DOC>
	<DOCNO>NCT02188277</DOCNO>
	<brief_summary>1 . To assess clinical neurophysiological efficacy Xeomin速 vs. Botox速 child spastic equine equinovarus foot deformation pediatric cerebral palsy 2 . To assess safety Xeomin速 use compare Botox速 patient population</brief_summary>
	<brief_title>Treatment With Xeomin Versus Botox Children With Spastic Equine Equinovarus Foot Deformation Pediatric Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<mesh_term>Paraplegia</mesh_term>
	<mesh_term>Clubfoot</mesh_term>
	<mesh_term>Equinus Deformity</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Children 2 12 year age , sex , suffer spastic paraplegia hemiparesis pediatric cerebral palsy . Equine equinovarus foot posture . Gastrocnemius spasticity 2 point great , modify Ashworth scale . Patient walk unassisted support . Mental development patient normal mildly retard . Previous course spasticity treatment BTA product complete early 6 month trial never administer . Patient 's parent sign informed consent , able wish adhere procedure describe trial protocol schedule visit throughout entire period treatment . Fixed ankle joint contracture . Previous denervation spastic muscle surgery , phenol alcohol ; Athetosis dystonia area inject muscle . Inflammation plan injection site . Elevated body temperature acute ( infectious noninfectious ) diseases time injection . Neuromuscular transmission disorder ( myasthenia gravis , LambertEaton syndrome , etc. ) . Decompensated physical disease potentially affect trial finding . Acute fever , infection surgery within 1 month trial . Use aminoglycosides spectinomycin within 1 month start trial . Hypersensitivity product ingredient . Positive history allergy ( especially regard proteincontaining product ) . Patient 's parent unable unwilling adhere trial protocol requirement include signing informed consent conform schedule visit . Participation clinical trial last 4 week inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>